Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Energy

Elixir Energy secures A$400,000 R&D rebate and debt facility for Daydream-2 Well

Elixir Energy Ltd (ASX:EXR) is set to receive a research and development (R&D) rebate of $400,000 for FY23. The rebate comes after the company receiving an advanced finding from the Australian Government’s Department of Industry, Science and Resources that activities associated with its Daydream-2 well (part of the Grandis Gas Project in Queensland) will qualify as eligible R&D activities for the purpose of the R&D tax incentive.

The rebate is 48.5% of the qualifying expenditure for the project and is due to be received shortly.

Elixir will incur most of its qualifying R&D expenses for its Daydream-2 project in FY24.

“The R&D rebate for Daydream-2 of around half of the total costs of the well is a very attractive form of non-dilutive funding for Elixir,” Elixir managing director Neil Young said.

“We are pleased to work with Radium Capital to provide us with a very simple and effective debt facility to optimally manage our cash-flows in 2024.”

Non-dilutive funding

To manage cash flows efficiently related to the R&D rebate for the year, the company has recently secured a term sheet agreement with Radium Capital, a preeminent provider of R&D finance that offers companies liquidity by giving early access to anticipated R&D tax rebates.

The agreed debt facility is straightforward and includes:

  • funding up to 80% of the expected rebate;
  • a fixed interest rate of 16%;
  • security against the R&D rebate due; and
  • absence of additional fees, conversion rights, or options.

This agreement will allow Elixir to maintain cash flow while eliminating the need for dilutive equity.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK